Atlas Trials

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

171 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

RecordFirmDate
Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr (NCT06799624)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2026-01-01
Microbiota-guided Radiotherapy for Head and Neck Cancer (NCT07253402)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2025-10-15
Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer (NCT06938724)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2025-07-25
Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma (NCT06986486)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2025-06-01
Revisiting the Concept of Nerve Sparing Radical Hysterectomy (NCT06999824)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2025-06-01
Immunological Phenotype of Desmoid-fibromatosis-affected Patients. (NCT07496242)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2025-05-27
Liver Transplantation for Unresectable Intrahepatic Colangiocarcinoma After Sustained Response to Neoadjuvant Treatments (NCT06862934)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2025-03-20
A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma (NCT07507578)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2025-03-01
Matching Primary Tumor and Blood Gene Expression Analysis of HPV-negative Squamous Head and Neck Cancers (NCT07512921)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2025-02-18
Xpert Bladder Monitor: a Non-Invasive Follow-Up Tool for Detecting Relapse in High Grade or High Risk Bladder Cancer (NCT06751667)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2025-01-01
Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer (NCT06528483)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2024-12-02
Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients (NCT06800391)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2024-11-22
A Composite Assay for HER2-positive Early-stage Breast Cancer Management (NCT06762977)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2024-11-13
High Versus Lower Intensity Surveillance Following Resection of Retroperitoneal Sarcoma (NCT06480396)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2024-11-01
A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL) (NCT06594679)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2024-09-26
Validation of the European Oncology Quality of Life Toolkit (NCT05947903)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2024-08-31
Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare) (NCT07461246)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2024-05-13
Fertility-sparing in Early-stage Cervcial Cancer: The ETERNITY Project (NCT06351228)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2024-03-30
Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS) (NCT06361784)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2024-03-29
Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer (NCT06726291)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2024-02-26
RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study (NCT07030569)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2024-02-01
Effects of Diet and Osteopathy on Quality of Life and Inflammation in Breast Cancer Patients Under Hormonal Therapy (NCT06164119)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2023-12-19
The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN) (NCT06408441)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2023-12-01
Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC) (NCT06086288)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2023-11-01
A Retrospective Study on Multiple Classifier Endometrial Cancer (NCT05976113)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2023-07-27
Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial (NCT05763992)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2023-05-15
Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study (NCT06805812)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2023-05-01
AI for Lung Cancer Risk Definition in Computed Tomography Screening Programs (NCT06320184)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2023-04-30
Pilot Study on the Use of iENTER, iCONSENT and iPARTICIPATE E-tools (NCT06317961)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2023-04-05
Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment (NCT05649943)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2023-03-01
Multiomics Approach in Metastatic Clear Renal Cell Carcnoma (NCT05782400)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2023-02-28
Indocyanine Green-guided Lymphadenectomy in Laparoscopic Total Mesorectal Excision for Low Rectal Cancer After Neoadjuvant Chemoradiotherapy (NCT05873621)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2023-01-01
FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction (NCT05703997)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2023-01-01
The ImmunoXXL Study (NCT05879328)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2022-12-23
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy (NCT05537922)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2022-10-01
APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch (NCT05550961)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2022-10-01
Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable Prognosis (NCT05754788)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2022-09-19
The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers (NCT05483374)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2022-05-31
Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy (NCT05031975)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2022-05-02
Mini-invasive Detection of Residual Disease in Breast Cancer Patients in Remission After Primary Chemotherapy (NCT05951699)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2022-04-28
Big Data for Quality of Life in Head and Neck Cancer (NCT05315570)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2022-03-28
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy (NCT05621837)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2022-03-10
Desmoid Tumor and Pregnancy: Effect of Pregnancy on Disease Control and Effect of Diagnosis on Pregnancy History. (NCT05284305)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2022-03-01
Predictors of Node Positivity in Endometrial Cancer (NCT05793333)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2022-01-10
TSH Suppression During Radiotherapy on Thyroid Site to Prevent Iatrogenic Hypothyroidism in Pediatric Cancer Patients (NCT05316922)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2021-12-13
Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer (NCT05136326)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2021-12-01
Palliative Care Referral System (PCRS) for Cancer Patients With Advanced Disease (NCT04936568)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2021-07-14
Collecting Ducts Carcinoma: in Depth Exploration and Biologically Driven Therapy (CICERONE) (NCT05372302)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2021-07-08
Patient-tailored Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases (OrganoHIPEC) (NCT06057298)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2021-06-15
Non-invasive Detection of Breast Cancer by Breath Analysis (NCT06499077)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2021-06-03
Adjuvant Pressurized Intraperitoneal Aerosol Chemotherapy to Prevent Colorectal Peritoneal Metastases (ProphyPIPAC) (NCT06091683)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2021-04-30
Epithelioid Haemangioendothelioma Observational Study (NCT06680401)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2021-02-25
Radiomics and Molecular Classification in Endometrial Cancer (NCT06963385)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2021-01-15
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. (NCT04689347)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2021-01-01
The TI.VA Algorithm: A First-in-Humans Test. (NCT05199883)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2020-12-01
A Comparison Between TOF Watch® SX and Tetragraph® (NCT04947306)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2020-08-24
Radiomics and Machine Learning in the Diagnosis of Ovarian Masses (NCT06342934)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2020-07-22
Multimodality Treatments of HPV-related Lesions of the Female Genital Tract (NCT05938192)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2020-07-15
Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment (NCT04435964)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2020-06-25
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (NCT04427787)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2020-06-20
Peritoneal Lavage Liquid Biopsy in Patients With Gastric Cancer (NCT04943406)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2020-05-08
Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer (NCT04248998)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2020-05-05
Effects of Acute and Chronic Exercise on Myeloid-Derived Suppressor Cells in Melanoma Patients (NCT05615883)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2020-01-20
The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study. (NCT04403867)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2020-01-02
Adjuvant VaccInation After Conization for the Treatment for CervicAL Dysplasia (NCT06611020)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2020-01-01
Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases (NCT04001725)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2019-10-15
hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study" (NCT03824691)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2019-09-25
Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen) (NCT03943602)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2019-08-01
Screening and Multiple Intervention on Lung Epidemics (NCT03654105)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2019-07-23
FOUND - Ancillary Study to Smile Protocol NCT03654105 (NCT04441814)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2019-07-23
Perioperative Residual Adrenal Function After Extended Resection for Retroperitoneal Soft Tissue Sarcomas (NCT04225494)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2019-06-01
PATIENT VOICES Integration of Systematic Assessment of Patient Reported Outcomes Within Clinical Oncology Practice (NCT03968718)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2019-05-27
Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study (NCT03832673)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2019-05-22
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer (NCT03832621)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2019-03-25
Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma (NCT03464734)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2019-01-16
Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation (NCT03803436)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2019-01-02
Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients (NCT05321329)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2018-12-03
Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab (I-Rene Trial) (NCT04891055)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2018-11-29
Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance (NCT03666325)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2018-10-01
Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer. (NCT03467178)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2018-07-30
Cancer Anesthesia and Frailty (NCT03575416)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2018-07-03
Impact of Dietary Intervention on Tumor Immunity: the DigesT Trial (NCT03454282)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2018-07-01
A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma (NCT03463681)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2018-06-11
Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer (NCT03539328)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2018-06-01
Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors. (NCT03447678)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2018-05-23
NICSO National Study: Physician - Nurse Monitoring Project About Oncological Adverse Events (NCT04726020)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2018-03-01
Duodenal Polyposis Classification in FAP (NCT07199127)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2018-02-02
caBozantinib in cOllectiNg ductS Renal Cell cArcInoma (NCT03354884)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2018-01-12
Preventive Anti-inflammatory Diet to Reduce Gastro-intestinal Inflammation in FAP Patients: a Prospective Pilot Study (NCT04552405)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2017-09-12
Hysteroscopic vs. Cervical Injection for Sentinel Node Detection of Endometrial Cancer (NCT04302714)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2017-03-20
A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease. (NCT03103724)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2017-03-16
Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) (NCT03449173)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2017-03-02
Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma (NCT02736266)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2017-02-27
Predictors of Normal Tissue Response From the Microenvironment in Radiotherapy for Prostate and Head-and-neck Cancer (NCT03294122)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2017-02-02
Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors (NCT03081923)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2017-02-01
Nutritional Status in Retroperitoneal Sarcoma. (NCT03877588)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2016-12-06
Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers (NCT02934464)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2016-12-01
REtroperitoneal SArcoma Registry: an International Prospective Initiative (NCT03838718)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2016-09-01
Second Line Sorafenib After Pazopanib in Patients With RCC (NCT02122003)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2016-09-01
DianaWeb: Before and After Study Online Based Participatory Research on Breast Cancer Women (NCT05057598)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2016-06-21
Next →

Track Fondazione IRCCS Istituto Nazionale dei Tumori, Milano automatically

Every clearance here is in the API, with alerts when new ones post.